Physiomics Regulatory News (PYC)

22 October 2020

GENERAL TEXT AMENDMENT: The following amendment has been made to the 'Posting of Annual Report and AGM Notice' announcement released at 7:00 a.m. this morning under RNS No 8073C.

"…the Company's AGM will be held at 10.00 a.m. on 17 November 2019 2020."

All other text remains unchanged. The full amended text is shown below.

Physiomics plc

("Physiomics" or "the Company")

Posting of Annual Report and AGM Notice

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has today posted to shareholders its Annual Report and Accounts for the financial year ended 30 June 2020, together with its Notice of Annual General Meeting ("AGM").

As announced on 30 September 2020, the Company's AGM will be held at 10.00 a.m. on 17 November 2020, at the Company's registered office, The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford, OX4 4GA.

As a result of UK Government guidance in respect of COVID-19, shareholders should note that they are not entitled to attend the AGM in person unless notified otherwise via an announcement on a Regulatory Information Service, which will also be displayed on the Company's website at www.physiomics.co.uk.

A copy of the Notice of AGM, containing further details of the resolutions, as well as a copy of the Company's Annual Report and Accounts will be made available today on the Company's website at www.physiomics.co.uk/investors/reports-prospectus/.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0)20 7409 3494

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0)20 3764 2341

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

For more information please visit:

www.physiomics.co.uk

www.twitter.com/Physiomics

www.linkedin.com/company/physiomics-plc/